Jacques Galipeau, MD FRCP(C)

Biography

Jacques Galipeau, MD FRCP(C)

Email: jgalipe@emory.edu

Dr. Galipeau is a Professor of Hematology and Medical Oncology, Pediatrics & Medicine, Emory School of Medicine and is Co-Director of the Winship Cancer Institute Tumor Immunology-Immunotherapy initiative as well as Director of the Emory Personalized Immunotherapy Center (EPIC) and has been named a Georgia Cancer Coalition Distinguished Cancer Scholar. Dr. Jacques Galipeau obtained his Medical Degree from the University of Montreal in 1988 and completed specialty training in internal medicine at the McGill-affiliated Jewish General Hospital. He went on to the Tufts-affiliated New England Medical Center in Boston for three years of subspecialty training in Hematology and Oncology followed by a two-year scientific fellowship in gene Therapy at St-Jude Children’s research hospital in Memphis Tennessee. In his 12 year career at McGill University starting in 1997, he initiated and developed a research program in cell and immunotherapy of catastrophic illnesses including cancer, immune and cardiovascular disease. The development of regenerative medicine and innovative cell-based therapies are on-going research and development interests pursued at Emory University since October 2009.

Since 1997, Dr. Galipeau has initiated and developed a research program in cell and gene therapy of catastrophic illnesses including cancer, immune and cardiovascular disease.    The goal of Dr. Galipeau’s research is to continue the development of a remarkable new class of biological agents we invented: the GIFT fusokines. These are in essence fusion proteins borne of GMCSF (at the N-terminus) and interleukins (at the C-terminus) whose acquired immunobiological properties render them extremely attractive as a novel biopharmaceutical strategy to treat cancer. Dr. Galipeau’s team is studying the use of GIFT21 in vitro, in mouse models of cancer and in human cells.

As co-Director for the Tumor Immunology Immunotherapy Program within the Winship Cancer Institute, Dr. Galipeau’s mandate is to develop and implement innovative trans-disciplinary translational (bench to bedside) research in cell-based and biological therapeutics and Tumor Immunotherapy.